Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

Merck (MRK) presented one-year results from the BRUNELLO trial of remigromig for diabetic macular edema, showing non-inferiority to ranibizumab but no superiority. Both doses met primary endpoints, with mean BCVA gains of +9.1 and +8.7 letters vs. +11.8 for ranibizumab. Adverse events were more frequent with remigromig.

Original reporting
Published Oct 10, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 — source image
Decision brief

The 30-second read

$MRKBearishLow
01

Why it matters

The BRUNELLO data provide the first efficacy read‑out for a Wnt‑pathway agonist, informing investor expectations for upcoming BAROLO results.

02

Market read

First disclosure of pivotal trial data for a novel ophthalmology therapy; may influence Merck's stock and sector peers.

03

What to watch

Potential for remigromig to address unmet patients who fail anti‑VEGF therapy, and long‑term market share if later trials show superiority.

Relevance 8/10Novelty 8/10Timing: presented today at AAO 2026

Background

Merck's ophthalmology pipeline aims to expand treatment options for retinal diseases beyond anti‑VEGF therapies.

Company-level read

Ticker impact

$MRKBearishHigh confidence
Context

Merck presented first one-year pivotal Phase 2b/3 BRUNELLO trial results for remigromig in DME, showing non‑inferior visual acuity versus ranibizumab.

Expected impact

likely modest pressure as investors weigh non‑inferiority and safety concerns

Evidence & confidence

First‑time disclosure of trial outcomes with no superiority and safety signals reduces enthusiasm for the asset.

Market effects

May temper enthusiasm for Wnt‑pathway ophthalmology programs and affect peer biotech valuations.

Limited to US biotech/ophthalmology investors.

Modest, as the trial is early‑stage and impacts a niche therapeutic area.

Counterpoint

The non‑inferior result could be a stepping stone; future Phase 3 data may still unlock value if safety improves.

Key entities

  • Merck

    Pharmaceutical company presenting the trial results.

  • Remigromig (MK-3000)

    Investigational tri‑specific antibody targeting the Wnt pathway.

Related articles

$MRKMed

Merck TroFuse-015 Phase 3 Meets Survival Endpoint — CASRAI

Merck announced that its Phase 3 trial of sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in patients with advanced gastroesophageal adenocarcinoma. The drug showed a statistically significant improvement in survival compared to physician's choice treatments, though secondary endpoints were not met. Full results will be presented at an upcoming medical meeting. Sac-TMT is not yet approved for any use.

$MRKHighAI 9/10

Merck Buys San Diego's Cidara Therapeutics for $9.2 Billion

Merck completed its $9.2 billion acquisition of Cidara Therapeutics, gaining control of CD388, an experimental flu drug. CD388 showed 76.1% efficacy in preventing flu in healthy adults in a Phase 2b trial, but further testing is needed for high-risk groups. Merck paid $221.50 per share for Cidara, with 85.96% of shares tendered. The FDA granted CD388 Breakthrough Therapy Designation, and Phase 3 trials are ongoing.

$MRKMedAI 8/10

Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma

Merck's phase 3 TroFuse-015 trial showed sacituzumab tirumotecan improved overall survival in pretreated gastroesophageal adenocarcinoma patients, meeting its primary endpoint. The trial enrolled 473 patients, comparing the drug to treatment of physician's choice. Secondary endpoints like progression-free survival were not met, but the drug's safety profile was consistent with prior studies. Merck plans to discuss the data with regulators and present it at an upcoming medical meeting.